PTLA - Portola Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.70
+0.68 (+2.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close33.02
Open32.98
Bid32.62 x 1400
Ask34.47 x 1300
Day's Range32.02 - 33.90
52 Week Range14.81 - 45.60
Volume869,533
Avg. Volume1,258,320
Market Cap2.252B
Beta (3Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-5.30
Earnings DateMay 7, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.40
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2019, and provide a general business overview on Wednesday, May 8, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban or apixaban.

  • Portola Pharmaceuticals: Is It Still a Buy?
    Motley Fool8 days ago

    Portola Pharmaceuticals: Is It Still a Buy?

    This commercial-stage company's success depends heavily on the demand for one drug.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

    Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PTLA are favorable, with net inflows of $2.51 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote
    American City Business Journals25 days ago

    Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote

    After all, the South San Francisco drug developer won two Food and Drug Administration approvals last year and, after slow sales of one of those drugs, it has focused on fixing manufacturing issues, nabbing European regulatory approval and getting hospitals to use the second drug, called Andexxa. At the same time, Portola (NASDAQ: PTLA) is moving forward with mid-stage studies of an experimental blood cancer drug. "Any biotech company can get bought," said Garland, who took over in October after the departure of Bill Lis, "but that's not where we spend our time." Yet with Portola's infrastructure built out, it is more attractive to larger companies that want the potential of Andexxa, the company's first-in-class antidote to blood-thinning drugs when a patient has uncontrolled bleeding.

  • Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
    American City Business Journals26 days ago

    Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

    How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.

  • CNW Grouplast month

    HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

    HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

  • GlobeNewswirelast month

    Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire from the Board of Directors. Dr. Homcy co-founded the Company in 2003 and served as president and chief executive officer until April 2010, when he transitioned into his role on the Board of Directors, and became Chair of the Board’s Research and Development Committee.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PTLA earnings conference call or presentation 1-Mar-19 1:30pm GMT

    Q4 2018 Portola Pharmaceuticals Inc Earnings Call

  • GlobeNewswirelast month

    Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive.

  • Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call Transcript

    PTLA earnings call for the period ending December 31, 2018.

  • Why Portola Pharmaceuticals Skyrocketed 15.3% Today
    Motley Fool2 months ago

    Why Portola Pharmaceuticals Skyrocketed 15.3% Today

    The company's latest quarterly update is sparking optimism that sales might accelerate.

  • GlobeNewswire2 months ago

    European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authorization application (MAA) for Ondexxya™ (andexanet alfa). The Committee has recommended that the European Commission (EC) grant Ondexxya conditional approval for the reversal of the anticoagulant effects of the Factor Xa inhibitors apixaban or rivaroxaban in patients experiencing uncontrolled or life-threatening bleeding.

  • Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million
    American City Business Journals2 months ago

    Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million

    The startup is tapping a wealth of genetic information in databases and a new wave of technology in its quest to figure out why some people with a genetic mutation can have a more-severe form of a disease than others with the same mutation.

  • Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know

    Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire2 months ago

    Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding

    Portola Pharmaceuticals, Inc.® (PTLA) today announced full results from ANNEXA-4, the Company’s Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] in patients experiencing acute major bleeding while taking a Factor Xa inhibitor. Anti-Factor Xa activity is a measure of the anticoagulant activity of apixaban, rivaroxaban, edoxaban and enoxaparin, the anticoagulants studied in ANNEXA-4.

  • Is There An Opportunity With Portola Pharmaceuticals, Inc.’s (NASDAQ:PTLA) 22.17% Undervaluation?
    Simply Wall St.3 months ago

    Is There An Opportunity With Portola Pharmaceuticals, Inc.’s (NASDAQ:PTLA) 22.17% Undervaluation?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $60 prize! I am going to run you through how I calculated Read More...

  • GlobeNewswire3 months ago

    Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and full year ended December 31, 2018, and provide a general business overview on Friday, March 1, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban.

  • GlobeNewswire3 months ago

    Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] have been accepted as a late-breaking oral presentation during the International Stroke Conference (ISC) 2019. Andexxa received both U.S. Orphan Drug and U.S. Food and Drug Administration (FDA) Breakthrough Therapy designations, and was approved on May 3, 2018 under the FDA's Accelerated Approval pathway.

  • GlobeNewswire3 months ago

    Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer

    Portola Pharmaceuticals, Inc.® (PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately. Mr. Koenig brings to his new role more than three decades of global commercial leadership and operations experience.

  • Why Portola Pharmaceuticals Rose 8.09% on January 4
    Market Realist3 months ago

    Why Portola Pharmaceuticals Rose 8.09% on January 4

    Why Portola Pharmaceuticals Rose 8.09% on January 4 ## Stock performance On January 4, Portola Pharmaceuticals stock closed at $19.38, an 8.09% increase from its prior close of $17.93 on January 3. On December 31, 2018, Portola Pharmaceuticals stock price grew ~14.22% to reach $19.52 from its prior close of $17.09 on December 28. The stock price on January 4 was ~65% below its 52-week high of $55.48 on January 29, 2018. The company hit its 52-week low of $14.81 on December 24, 2018. ## Recent developments On December 2018, the US FDA (Food and Drug Administration) approved Portola Pharmaceuticals’ PAS (prior approval supplement) for large-scale, second-generation Andexxa. The approval enables a wide commercial launch of Andexxa in the US market. In May 2018, the FDA approved Andexxa under the accelerated approval pathway. The FDA also granted Andexxa an orphan drug designation and a breakthrough therapy designation. The approval is expected to boost the commercial launch of Andexxa in the US market, which in turn could significantly boost the revenue growth of Portola in 2019. ## Financials in a nutshell In the first nine months of 2018, Portola Pharmaceuticals’ net revenues grew ~95% YoY to reach $24.8 million from $12.7 million. Wall Street analysts estimate that Portola Pharmaceuticals will generate net revenues of $35.70 million, which represents ~58.35% YoY growth. The revenue growth of Portola Pharmaceuticals (PTLA) could boost the SPDR S&P Biotech ETF (XBI). The company makes up about ~1.31% of XBI’s total portfolio holdings. In the first nine months of 2018, Portola reported net income and EPS of -$261.7 million and -$3.97, respectively, compared to -$194.3 million and -$3.38 in the same period the prior year. Wall Street analysts estimate that Portola Pharmaceuticals will report net income and EPS of -$333.57 million and -$5.03, respectively, in fiscal 2018. ## Analysts’ recommendations Of the seven analysts tracking Portola Pharmaceuticals in January 2019, three of them recommended a “strong buy,” two analysts recommended a “buy” rating, and two analysts recommended a “hold” rating. On January 7, 2019, the company had a consensus 12-month target price of $35.83, which represents a ~84.88% return on investment over the next 12 months.